Weglim-M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, promoting better glucose uptake by muscle tissues. The sustained-release formulation of Weglim-M2 ensures gradual drug release, improving glycemic control while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Weglim-M2 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in conditions predisposing to lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to ensure safety and efficacy.